Celprogen Inc. has announced that they have successfully De-DIFFERENTIATED Human Somatic Cells (primary skin fibroblast, keratinocytes, cardiac, liver and neuronal cells) to their embryonic like pluripotent cells (iPCs).

This De-differentiation process was achieved with non-viral induction utilizing Celprogen's De-differentiation media and matrix system for reprogramming adult somatic cells to iPCs in tissue culture.

The adult somatic cells were De-differentiated (reprogrammed) into their progenitor cell stage and then further de-differentiated into their resident pool of embryonic stem cell like linage. The de-differentiated somatic cells were further differentiated to the following tissue types in culture cardiac, neuronal and hepatocytes with Celprogen's Stem Cell Differentiation system. The De-differentiation process is a non-viral process that brings promise for therapeutic applications in the near future.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique cancer therapeutics products and life science tools that includes stem cell technologies for regenerative medicine, as well as bioengineering products for tissue and organ transplants. Headquartered in San Pedro, California, Celprogen is committed to research, development and manufacture of quality stem cell products to serve our global community.

Celprogen Inc.

Tag Cloud